Kimberly Murphy

Oragenics CEO Stepping Down

UF Innovate | Accelerate Sid Martin graduate company Oragenics announced on Monday that their CEO, Kimberly Murphy, would be stepping down. Murphy and the company said they had come to a mutual separation agreement. The board appointed Michael Redmond, company president, as interim "principal executive officer". Murphy served as CEO since June 2022, and the company said the decision was not the result of a disagreement. She has been on the board for Oragenics since 2020 and previously served as vice president of GSK, where she helped develop vaccines for influenza and shingles.

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’s HPV/Gardasil Franchise. Ms. Murphy joined Oragenics’ Board of Directors in 2020.